MedTrace Logo

Combination Therapy for Warts: Candida Antigen vs. Topical Keratolytic

NCT07329907 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2026-01-09

No results posted yet for this study

Summary

Objective: To compare the efficacy, safety, and recurrence rates of topical salicylic acid/lactic acid (SA/LA) monotherapy (Group A), intralesional Candida antigen (CA) monotherapy (Group B), and their combination (Group C) for the treatment of warts.

Conditions

  • Warts
  • Human Papilloma Virus (HPV)

Interventions

DRUG

Salicylic Acid/Lactic Acid Topical Solution

Patients receive topical application of Salicylic Acid 40% and Lactic Acid 16% once daily for up to 6 weeks.

BIOLOGICAL

Candida Antigen Intralesional Injection

Patients receive intralesional injection of Candida Antigen (0.1-0.3 mL) every 2 weeks for up to 6 sessions.

COMBINATION_PRODUCT

Candida Antigen and Salicylic Acid/Lactic Acid

Patients receive intralesional injection of Candida Antigen (0.1-0.3 mL) every 2 weeks for up to 6 sessions, with topical Salicylic Acid 40% and Lactic Acid 16% applied in between.

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Ghada Shams · Benha University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-06-01
Completion
2024-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07329907 on ClinicalTrials.gov